Delivery Order SPE2DB20D3103-SPE2DB25FQ1M6
- Not listed
- The Defense Logistics Agency awarded a $279,751.97 delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of SKYRIZI 150 MG/ML in pen/milliliter formulation. This is a firm fixed price contract with no set-aside designation, executed as a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The contract is set to be completed by September 9, 2025, with fulfillment occurring at AmerisourceBergen's corporate...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $46,515.57 to AmerisourceBergen Drug Corp for the supply of SKYRIZI 150 MG/ML pen/milliliter on August 5, 2025, with an ultimate completion date of August 6, 2025. This competitively awarded, firm fixed-price contract involves no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 12, 2025, for the supply of SKYRIZI 150 mg/ml in pen/ml formulation, with a ceiling value of $24,342.14. This is a firm fixed price, non-set-aside contract with an ultimate completion date of September 15, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order valued at $26,227.70 to AmerisourceBergen Drug Corp for SKYRIZI 150 MG/ML pen/milliliter pharmaceutical product on June 2, 2025, with a completion date of June 3, 2025. This competitively awarded, firm fixed-price delivery order was issued without a set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. SKYRIZI is a biologic medication used in the treatment of inflammatory skin...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $16,842.74 to AmerisourceBergen Drug Corp for the supply of SKYRIZI 150 MG/ML PENFILL, a pharmaceutical product. The contract is a firm fixed price delivery order with an ultimate completion date of August 4, 2025, and carries no set-aside designation, indicating it was awarded through competitive procurement. The place of performance is located in Conshohocken, Pennsylvania, the company's headquarters. This delivery order...
- This delivery order, awarded on September 19, 2025, by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, covers the supply of SKYRIZI 150 mg/ml in pen format with a ceiling value of $59,150.00 and firm fixed pricing. The order is set to complete by September 22, 2025, and will be fulfilled from the contractor's facility in Conshohocken, Pennsylvania. This is a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $26,093.66 to AmerisourceBergen Drug Corp for the supply of SKYRIZI 150 MG/ML in pen/milliliter format. The contract is a firm fixed-price delivery order with an ultimate completion date of September 11, 2025, and was awarded on September 10, 2025. The contract carries no set-aside designation and represents a competitively awarded transaction. Performance will be fulfilled from AmerisourceBergen Drug Corp's Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $11,830.00 to AmerisourceBergen Drug Corp for SKYRIZI 150 MG/ML pen/mL pharmaceutical product. The contract, awarded on September 2, 2025, with completion targeted for September 3, 2025, utilizes firm fixed pricing with no set-aside designation. This delivery order represents a competitive award under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $33,797.51 to AmerisourceBergen Drug Corp for the supply of SKYRIZI 150 mg/ml pen injectors. This competitive award, issued on July 22, 2025, with an ultimate completion date of July 23, 2025, represents a firm fixed-price delivery order with no set-aside designation. The contract is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for SKYRIZI 150 MG/ML in pen/milliliter format, with a contract ceiling value of $20,981.41. This firm fixed-price delivery order, awarded on September 3, 2025, with an ultimate completion date of September 4, 2025, represents a non-competitive set-aside contract. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. As a major...
- SPE2DB20D3103Indefinite Delivery Contract
- SPE2DB20D3103-SPE2DB25FQ1M6Delivery Order
The Defense Logistics Agency (DLA) awarded a $11,830.00 delivery order to AmerisourceBergen Drug Corp for SKYRIZI 150 MG/ML pen/milliliter pharmaceutical product on September 4, 2025, with completion expected by September 5, 2025. This is a firm fixed-price contract with no set-aside designation, competitively awarded to the prime contractor. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The IDC serves as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply a broad range of pharmaceuticals and medical supplies to military healthcare programs and the Defense Health Agency worldwide. SKYRIZI is a specialty dermatological medication, consistent with AmerisourceBergen's extensive portfolio of brand-name and generic pharmaceutical products, vaccines, and medical supplies delivered through DLA's medical supply chain to support federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $11.8k | 9/4/25 |